Inkretine als Grundlage der Adipositastherapie.
Incretins as the basis of obesity treatment.
Innere Med. 66, 461-466 (2025)
Obesity represents an immense challenge for patients and physicians due to its numerous comorbidities and complications. For a long time, safe and effective pharmacological treatment remained wishful thinking. Bariatric surgery was considered the only option for sustained weight loss; however, with the advent of incretin-based treatment, initially introduced as a highly effective component of anti-diabetic treatment, research began to focus on the complex gastroenteropancreatic endocrine system, including central hunger and satiety regulation. This shift was driven by the discovery of a remarkable side effect: placebo-controlled weight reduction. Subsequent groundbreaking pharmacological developments based on long-acting peptides, the administration of which could be reduced from twice daily in earlier forms of treatment to once weekly, now enables significant weight reduction of over 20%, with a tolerable safety profile. This article provides an illustrative overview of the corresponding associations and highlights this milestone in obesity treatment.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Appetite Regulation ; Glucagon-like Peptide 1 (glp-1) ; Glucose-dependent Insulinotropic Polypeptide (gip) ; Obesity/drug Therapy ; Weight Loss; Appetite
Keywords plus
Sprache
deutsch
Veröffentlichungsjahr
2025
Prepublished im Jahr
0
HGF-Berichtsjahr
2025
ISSN (print) / ISBN
2731-7080
e-ISSN
2731-7099
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 66,
Heft: 5,
Seiten: 461-466
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Springer
Verlagsort
Heidelbergerplatz 3, Berlin, Germany
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-501900-221
Förderungen
Copyright
Erfassungsdatum
2025-05-10